Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
Frequently asked questions
What sector does Coeptis Therapeutics Holdings Inc (COEPW) operate in?
Coeptis Therapeutics Holdings Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Coeptis Therapeutics Holdings Inc (COEPW) current stock price?
As of the latest data, Coeptis Therapeutics Holdings Inc stock price is $0.01, with a previous close of $0.01.
What is Coeptis Therapeutics Holdings Inc (COEPW) current market capitalization?
Coeptis Therapeutics Holdings Inc market cap is approximately 60.32 thousand.
What is Coeptis Therapeutics Holdings Inc (COEPW) EBITDA?
Coeptis Therapeutics Holdings Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.51 million.
Does Coeptis Therapeutics Holdings Inc (COEPW) pay dividends?
No. Coeptis Therapeutics Holdings Inc does not pay a dividend.
What is Coeptis Therapeutics Holdings Inc (COEPW) beta (volatility) score?
Coeptis Therapeutics Holdings Inc has a beta of -0.590, indicating lower volatility than the overall market.
